HER-2/neu expression in breast cancers (HER-2/neu phenotype and Luminal B) is associated with poor prognosis high risk breast cancers. Targeting HER-2/neu in early breast cancer using vaccine approaches may eliminate this high risk phenotype and create estrogen receptorpos HER-2/neuneg (Luminal A) phenotypes that are more amenable to current standard treatments. In our previous funding period, we developed novel type I polarized dendritic cells (DC1) activated using toll like receptor agonists with the capacity for high level second burst interleukin-12 production. These DC1 pulsed with MHC class I and class II peptides derived from HER-2/neu administered in a neoadjuvant trial to patients with ductal carcinoma in situ (DCIS) resulted in near uniform sensitization of HER-2/neu specific CD4, and CD8 T cells, induction of complement fixing antibodies, and in half the patients accumulation of T and B cells in the breast. These immune responses appear to be long lasting. In addition, there was significant reductions in HER-2/neu expressing DCIS in about 50% of patients with apparent clinical reductions in the extent of disease. The latter results strongly suggest evidence for a paradigm we have identified as targeted immunoediting. In targeted immunoediting a more aggressive phenotype is targeted for elimination to create a more favorable phenotype, the reverse of natural immunediting. We have also made the striking observation as a result of our initial trial that HER-2/neu expression in DCIS appears to be highly associated with the development of invasive breast cancer. Therefore targeting HER-2/neu prior to development or in early disease settings may prevent the development of a significant number of invasive breast cancers. In the initial funding period we focused on developing an adaptive immune response by administering DC in a remote intranodal location however, the DC1 generated produce large quantities of cytokines and chemokines that can be taken advantage of to attract both innate and antigen specific effectors into the breast if administered into the region of cancer. Given the early success of this DC1 vaccination there is tremendous opportunity to explore the development of DC1 vaccines for the treatment of DCIS and the prevention of invasive breast cancer. In the current application we will extend our initial observations from the previous application to (1) Determine whether combined intranodal and intralesional HER-2/neu pulsed DC1 vaccinations will increase the clinical response rates by delivering innate immune effectors into the breast to increase the accumulation of both the innate (NK cells) and adaptive effectors into the area of DCIS this will be assessed in a randomized clinical trial using 3 routes of administration, intralesional, intranodal or both sites. (2), Determine the mechanism by which the DC1 vaccination induces clinical responses and immunoedits DCIS. This will be accomplished by evaluation of the immune response including cytokine chemokine production in the locoregional area including sentinel nodes and DCIS lesions and systemic peripheral blood, and perform a molecular profile of the edited DCIS lesions. It is anticipated that this program will identify the requirements for successful anti-cancer vaccine strategies in general and develop the groundwork for utilizing HER-2/neu vaccines for the treatment of early breast cancer. Success of the project may lead to new immunotherapies that can be utilized with existing standrard treatments for breast cancer, but more importantly pave the way for developing vaccines for breast cancer prevention.
HER-2/neu over-expressing DCIS represents a group of patients with significant risk for development of invasive breast cancer. In this proposal we will continue to evaluate the development of type I polarized DC for the treatment of DCIS by evaluating whether further improvements in therapeutic response can be achieved by intralesional administration of HER-2/neu pulsed DC1 compared with intranodal administration. It is anticipated that the production of chemokines and cytokines by DC1 will lead to accelerated accumulation of specific and non-specific effectors in the area of DCIS and further clinical responses.
|Roses, Robert E; Datta, Jashodeep; Czerniecki, Brian J (2014) Radiation as immunomodulator: implications for dendritic cell-based immunotherapy. Radiat Res 182:211-8|
|Koski, Gary K; Koldovsky, Ursula; Xu, Shuwen et al. (2012) A novel dendritic cell-based immunization approach for the induction of durable Th1-polarized anti-HER-2/neu responses in women with early breast cancer. J Immunother 35:54-65|
|Harada, Shuko; Mick, Rosemarie; Roses, Robert E et al. (2011) The significance of HER-2/neu receptor positivity and immunophenotype in ductal carcinoma in situ with early invasive disease. J Surg Oncol 104:458-65|
|Bahl, Susan; Roses, Robert E; Sharma, Anupama et al. (2009) Asymptomatic changes in cardiac function can occur in ductal carcinoma-in-situ patients following treatment with HER-2/neu-pulsed dendritic cell vaccines. Am J Surg 198:488-94|
|Roses, Robert E; Paulson, E Carter; Sharma, Anupama et al. (2009) HER-2/neu overexpression as a predictor for the transition from in situ to invasive breast cancer. Cancer Epidemiol Biomarkers Prev 18:1386-9|
|Roses, Robert E; Xu, Shuwen; Xu, Min et al. (2008) Differential production of IL-23 and IL-12 by myeloid-derived dendritic cells in response to TLR agonists. J Immunol 181:5120-7|
|Roses, R E; Xu, M; Koski, G K et al. (2008) Radiation therapy and Toll-like receptor signaling: implications for the treatment of cancer. Oncogene 27:200-7|
|Koski, Gary K; Cohen, Peter A; Roses, Robert E et al. (2008) Reengineering dendritic cell-based anti-cancer vaccines. Immunol Rev 222:256-76|
|Czerniecki, Brian J; Koski, Gary K; Koldovsky, Ursula et al. (2007) Targeting HER-2/neu in early breast cancer development using dendritic cells with staged interleukin-12 burst secretion. Cancer Res 67:1842-52|
|Czerniecki, Brian J; Roses, Robert E; Koski, Gary K (2007) Development of vaccines for high-risk ductal carcinoma in situ of the breast. Cancer Res 67:6531-4|
Showing the most recent 10 out of 12 publications